Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.4K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.4K
Forces Acting on Chromosomes02:11

Forces Acting on Chromosomes

3.9K
During mitosis, chromosome movements occur through the interplay of multiple piconewton level forces. In prometaphase, these forces help in chromosome assembly or congression at the equatorial plane, eventually leading to their alignment at the metaphase plate. The forces acting on the chromosomes are space and time-dependent; therefore, they vary with the position of the chromosomes as the cell progresses through mitosis. 
Microtubules and motor proteins exert two types of forces on...
3.9K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

840
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
840
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.4K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.4K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

1.8K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.8K
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

2.0K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD - A phase 2A clinical trial.

European journal of pharmacology·2025
Same author

Is there a continued need for behavioral pharmacology in the discovery and development of medicines?

The Journal of pharmacology and experimental therapeutics·2025
Same author

Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): Implications for the use of low impact ampakines in the treatment of schizophrenia.

Journal of psychiatric research·2025
Same author

Preclinical Pharmacology of CX1837, a High-Impact Ampakine with an Improved Safety Margin: Implications for Treating Alzheimer's Disease and Ischemic Stroke.

Current Alzheimer research·2025
Same author

Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today.

Pharmacology, biochemistry, and behavior·2025
Same author

Safety, tolerability and pharmacokinetic profile of the low-impact ampakine CX717 in young healthy male subjects and elderly healthy male and female subjects.

European journal of pharmacology·2025
Same journal

Preface.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

T Cell subsets for therapy-unconventional CD1d-restricted natural killer T cells.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Tracking therapeutic T cells in vivo.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

In vivo transduction of CAR T cells: Pharmacological principles, delivery platforms, and the road to clinical translation.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Transient T cell therapies.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Manufacturing as biology: How T-cell processing shapes therapeutic outcomes.

Advances in pharmacology (San Diego, Calif.)·2026
See all related articles

Related Experiment Video

Updated: Jan 21, 2026

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.7K

Rapid-acting antidepressants.

Jeffrey M Witkin1, Anna E Martin2, Lalit K Golani3

  • 1Witkin Consulting Group, Carmel, IN, United States; Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN, United States; Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, United States.

Advances in Pharmacology (San Diego, Calif.)
|August 6, 2019
PubMed
Summary
This summary is machine-generated.

New rapid-acting antidepressants show promise for treatment-resistant depression, offering faster relief than traditional options. Further research is needed to overcome side effects and ensure long-lasting antidepressant effects.

Keywords:
GABAA α5KetaminePsychedelic drugsRapid-acting antidepressantsScopolaminemGlu2/3 receptor antagonists

More Related Videos

Measurement of Dynamic Force Acted on Water Strider Leg Jumping Upward by the PVDF Film Sensor
07:17

Measurement of Dynamic Force Acted on Water Strider Leg Jumping Upward by the PVDF Film Sensor

Published on: August 3, 2018

6.4K
Combination of Adhesive-tape-based Sampling and Fluorescence in situ Hybridization for Rapid Detection of Salmonella on Fresh Produce
09:10

Combination of Adhesive-tape-based Sampling and Fluorescence in situ Hybridization for Rapid Detection of Salmonella on Fresh Produce

Published on: October 18, 2010

13.5K

Related Experiment Videos

Last Updated: Jan 21, 2026

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.7K
Measurement of Dynamic Force Acted on Water Strider Leg Jumping Upward by the PVDF Film Sensor
07:17

Measurement of Dynamic Force Acted on Water Strider Leg Jumping Upward by the PVDF Film Sensor

Published on: August 3, 2018

6.4K
Combination of Adhesive-tape-based Sampling and Fluorescence in situ Hybridization for Rapid Detection of Salmonella on Fresh Produce
09:10

Combination of Adhesive-tape-based Sampling and Fluorescence in situ Hybridization for Rapid Detection of Salmonella on Fresh Produce

Published on: October 18, 2010

13.5K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Conventional antidepressants targeting biogenic amines have limitations in efficacy, onset speed, and breadth of symptom coverage.
  • A new class of rapid-acting antidepressants has emerged, showing significant promise since 2006.
  • These novel agents demonstrate quick onset, substantial effect sizes, and efficacy in treatment-refractory depression.

Purpose of the Study:

  • To review the emerging landscape of rapid-acting antidepressants.
  • To discuss their mechanisms of action, clinical data, and potential for treating resistant depression.
  • To identify challenges and future directions in the development of these novel therapeutics.

Main Methods:

  • Review of clinical studies on rapid-acting antidepressants including ketamine, NMDA receptor antagonists, and scopolamine.
  • Examination of emerging psychedelic drugs like psilocybin and LSD for antidepressant potential.
  • Analysis of preclinical data for novel pharmacological classes targeting AMPA and GABA receptors.

Main Results:

  • Ketamine, other NMDA antagonists, and scopolamine show rapid antidepressant effects in clinical studies.
  • Psychedelic drugs (psilocybin, LSD) show potential but have less clinical data.
  • A common mechanism appears to involve potentiation of AMPA receptor function.
  • While ketamine and scopolamine effects are transient, psychedelics may offer longer-lasting benefits.
  • Esketamine is FDA-approved; (R)-ketamine, GLYX-13, and TAK-653 are in clinical development.

Conclusions:

  • Rapid-acting antidepressants offer a significant advancement over conventional treatments for depression.
  • Understanding and mitigating side effects, alongside ensuring durable effects, are key challenges.
  • Further exploration of diverse pharmacological targets is crucial for developing next-generation antidepressants.